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ABSTRACT 
Nearly 5% of the global population are burdened with depression and nearly 7% have an anxiety 
disorder. Adequate nutrient intake is paramount to human health, helping maintain homeostasis 
of physiological systems, and maintaining or modulating the gastrointestinal microbiota. Cross-
sectional and preclinical studies have demonstrated improvements to mental health following 
dietary interventions, but there is a dearth of evidence from clinical intervention trials to support 
dietary interventions strategies to treat the symptoms of depression, anxiety, or stress. In addition 
to diet, the gastrointestinal (GI) microbiota has also been associated with mood disorders. 
However, additional studies are needed to confirm if diet and/or the GI microbiota relate to 
changes in mood among adults.  
The objective of this research was to investigate links among diet, GI microbiota, and the 
negative emotional states of depression, anxiety, and stress. The review of literature revealed that 
the relationships between mood and GI microbiota is under investigated in populations without 
physician diagnosed mood disorders, diet is rarely measured or controlled for in research trials 
assessing connections between the GI microbiota and mood, and dietary and microbial 
connections to mood are typically studied independently, rather than together. 
Accordingly, a cross-sectional study in adults representative of the general public was 
undertaken to test the hypotheses that GI microbiota and diet are associated with the negative 
emotional states of depression, anxiety, and stress in adults without physician diagnosed mood 
disorders. Diet history questionnaires were utilized to assess habitual diet and fecal samples were 
analyzed to characterize the GI microbiota of participants. Mood was assessed using the 
Depression, Anxiety, and Stress Scale (DASS), which consists of three scales that measure the 
negative emotional states of depression, anxiety, and stress experienced within the past week. 
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These DASS score variables were assessed in relation to dietary components, diet quality, and 
bacterial relative abundances. Additionally, relations between DASS scores and bacterial relative 
abundances were assessed with and without dietary fiber in the statistical model. The analyses 
revealed relationships supported by existing literature and that relationships between mood and 
GI microbiota may be influenced by sex and dietary fiber intake. They also revealed that mood is 
associated with adequate fruit intake. 
Herein, we review the current literature and present novel findings from our original 
research. The results revealed associations among diet, the GI microbiota, and negative 
emotional states. Further study is warranted to determine if synergistic diet-microbiota therapies 
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CHAPTER 1: A review of dietary and microbial connections to depression, anxiety, and 
stress1 
Abstract 
Objective: Pre-clinical evidence suggests that the gastrointestinal microbiota 
contributes to mood and behavior disorders. Among humans, diet quality and 
patterns, which also impact the gastrointestinal microbiota, have been linked to 
depression, anxiety, and stress. This review summarizes findings from clinical 
studies using dietary intervention to improve depression, anxiety, or stress and the 
role the gastrointestinal microbiota may have in these disorders. 
Methods: A literature search was conducted using the keywords microbiome, 
microbiota, depression, anxiety, stress, diet, dietary pattern, diet quality, fiber, 
prebiotics, probiotics, and mood. 
Results: Mood was improved by enhancing diet quality. Fructooligosaccharides 
and galactooligosaccharides improved anxiety and depression in participants 
consuming ≥ 5g/day. Additionally, bifidobacteria were enriched in subjects 
consuming ≥ 5g/day. Probiotic consumption improved psychological or biological 
measures of depression, anxiety, or stress in individuals predisposed to a mood 
disorder. Probiotics suppressed biological markers of stress in healthy individuals 
in a strain-dependent manner. 
Discussion: High-quality diets, prebiotics, and probiotics may beneficially affect 
mood. Habitual diets rich in dietary fiber and omega-3-polyunsaturated fatty acids 
may be linked to reduced risk of developing symptoms of depression, anxiety, and 
stress; however, additional studies are necessary. Certain probiotics may enhance 
mood, but their influence on the gastrointestinal microbiota requires further 
investigation. 
Keywords: microbiome, probiotics, prebiotics, fiber, microbiota, mood, diet-quality
                                                 
1 The final, definitive version of this paper has been published in Nutritional Neuroscience, July 
2018 by Taylor and Francis Group © 2018 Informa UK Limited. The Authors. Taylor AM and 
Holscher HD. A review of dietary and microbial connections to depression, anxiety, and stress. 




There is increasing evidence that the gastrointestinal microbiota influences human health, and 
metabolic, gastrointestinal, and psychological diseases (1–3). Pre-clinical and clinical evidence 
suggest that the gastrointestinal microbiota influence mood and behavior, including depression, 
anxiety, and stress (4,5). Similarly, diet, eating behaviors, and consumption of fiber and prebiotic 
fibers affect the composition and metabolic functions of the human gastrointestinal microbiota 
(6–11). Clinical research has revealed diet quality, as well as specific dietary components and 
dietary supplements aid in prevention or treatment of symptoms of depression, anxiety, and 
stress. Specifically, high diet quality, prebiotic fiber consumption, and probiotic supplements 
reduced anxiety symptoms and had antidepressant effects in humans (12–15). The exact role the 
gastrointestinal microbiota play in the development of mental disorders is still being elucidated, 
but its involvement in bidirectional communication between the brain and gastrointestinal tract 
via the gut-brain axis is presumably a fundamental link between the microbiota and mood 
disorders. Delineating the relationship between diet, the gastrointestinal microbiota, and mental 
health is important for future applications of diet therapy for the treatment of depression, anxiety, 
and stress. 
Herein, we review and discuss dietary and microbial factors that may influence the 
symptoms of depression, anxiety, and stress. The primary focus of this article is on the outcomes 
from dietary intervention trials conducted on human subjects.  
Gut microbiota and mood 
The brain-gut-microbiota axis is a bidirectional communication network that allows 
gastrointestinal microbes to convey information to the brain, and for the brain to communicate 
 
 3 
with the gastrointestinal tract. The mechanisms by which microbes affect mood in humans are 
not fully known, but preclinical studies have demonstrated that the gut microbiota plays an 
important role in mental health (5,16–18). For example, depression symptoms have been 
transferred via fecal microbiota transplant from depressed humans to rodents (17,19). The gut 
microbiota of depressed individuals have been compared to healthy individuals and alterations at 
several taxonomic levels were reported (17). Notably, differences in the dominant phyla, 
Bacteroidetes, Firmicutes, and Actinobacteria, were observed (17,20), but the relative 
abundances of these phyla were not consistent between the two studies. Jiang et al. reported 
increased relative abundances of Bacteroidetes and Actinobacteria, among others, and decreased 
relative abundances of Firmicutes.  Zheng et al. similarly reported higher relative abundances of 
Actinobacteria; however, Bacteroidetes were lower, and no differences were observed in 
Firmicutes (17,20). Others have reported that Bacteroidetes is positively associated with 
depression (21). These conflicting results may, in part, be explained by a lack of control for diet 
as the aforementioned studies did not collect dietary data. As diet influences the gut microbiota 
(7,22), it may be contributing to the lack of consistency among trials.  
To understand the mechanisms and impact the gut microbiota have on mood, additional 
clinical trials are needed. Future studies should examine the role habitual dietary intake and 
dietary components have in altering gut microbiota of individuals with mood disorders. As we 
will discuss, dietary intervention has been reported to improve mood. However, human dietary 
interventions trials investigating the gut microbiota as a mediator of mood improvement are 
lacking.  
Diet quality and mood: observational studies 
Observational studies provide evidence linking poor diet quality to depression, while good diet 
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quality has been connected to a reduced risk of depression (23–26). Recently, a nine-year 
prospective cohort study reported a lower risk of depression for subjects in the highest tertile of 
diet quality compared to the lowest tertile (24). The Mediterranean diet has also been associated 
with a reduced risk of depression among participants with high and moderate adherence to the 
Mediterranean diet pattern (27). Interestingly, the Mediterranean diet, and other dietary patterns 
rich in fruits and vegetables, have been shown to beneficially impact the gut microbiota (27,28). 
Dietary patterns aimed at reducing diet inflammatory potential have been also connected to a 
reduced risk of depression (29–34). Dietary recommendations to reduce the risk of depression 
include increasing the intake of fruits, vegetables, fish, whole-grains, legumes, and olive oil, in 
conjunction with reducing the consumption of highly refined grains, red meat, fried foods, and 
sweets (35). 
The Mediterranean diet pattern has been connected to a reduced risk of depression (36–
38), presumably by altering pro-inflammatory mechanisms (39,40). The risk of developing 
depression has been linked to diets with high inflammatory potential, i.e., energy-dense foods, 
high-fat and high-sugar, refined-grains, and alcohol (32–34). The inflammatory potential of a 
diet can be measured using a dietary index, e.g., Dietary Inflammatory Index, which categorizes 
an individual’s diet on a continuum ranging from maximally anti-inflammatory to maximally 
inflammatory (29,32,34). The Mediterranean diet pattern has a low inflammatory potential (41).  
Systematic reviews and meta-analyses investigating the relationship between diet quality 
and depression have reported a relationship between measures of diet quality and depression 
(25,36,38,42). However, additional clinical intervention trials are needed to determine if there is 




The habitual intake of specific food groups has been associated with stress and depression. 
Specifically, sweets and fast-food are consumed more frequently in stressed and depressed 
individuals (43,44). Contrarily, fruits and vegetables are consumed less frequently by depressed 
individuals (43–46).  
Interestingly, the intake of dietary fiber derived from fruits and vegetables, but not total, 
soluble, or insoluble fiber intake, has been reported to be inversely related to depression 
symptoms (47,48). Dietary fibers comprise the cell walls of fruits and vegetables and are 
resistant to digestion by human enzymes, e.g., pectins, gums, and fructans, but may be 
metabolized by microbial enzymes in the gastrointestinal tract (49,50). Thus, these dietary fibers 
can be fermented by resident microbes, resulting in the production of short-chain fatty acids 
(SCFA) (51). SCFA, especially butyrate, play a crucial role in regulating intestinal epithelial 
barrier integrity by providing energy to intestinal epithelial cells and microbes, and by 
stimulating the secretion of glucagon-like peptides 1 and 2 (52). Glucagon-like peptides 1 and 2 
decrease the permeability of intestinal epithelial cells (52). Inadequate dietary fiber intake 
deprives microbes of a nutrient source and decreases butyrate-producing bacteria (27). To 
compensate, secreted mucus glycoproteins may be used as an alternative energy source (53), 
eroding the colonic mucus barrier, and compromising intestinal barrier protection. A reduction in 
butyrate-producing bacteria may compromise intestinal barrier protection (54,55). Accordingly, 
an increase in permeability allows the translocation of lipopolysaccharides, a component of the 
outer membrane of gram-negative bacteria and pro-inflammatory stimulus, into systemic 
circulation (56). Lipopolysaccharides play a significant role in chronic low-grade inflammation, 
a phenomenon known as endotoxemia (56). Inflammation is characteristic of depression (57). 
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Thus, SCFAs may indirectly influence mood by modulating intestinal permeability and systemic 
lipopolysaccharide circulation. 
In addition to providing a source of dietary fiber, fruits and vegetables are rich sources of 
antioxidants. Antioxidants play an important role in protecting cells from oxidative and 
nitrosative stress (ONS). ONS can damage cellular lipids, proteins, and DNA and cause cell 
death (58). ONS can also activate transcription factors, i.e., NF-κB, that lead to the expression of 
inflammatory cytokines (59,60). ONS and inflammation have been observed in depressed 
individuals (61,62). Dietary fiber and antioxidants are often consumed in low abundances in 
individuals following an unhealthy eating pattern (63). Antioxidants, e.g., polyphenols, may 
reach the large intestine in association with dietary fiber, and become dissociated when fiber is 
metabolized by colonic microbiota (64,65). Extraction, metabolization, and absorption of 
polyphenols from dietary fiber in the gastrointestinal tract are dependent on bacterial enzymes. 
Additionally, polyphenolics can modulate the gastrointestinal microbiota (66,67) and act as 
antimicrobial or anti-inflammatory compounds (68–70). Thus, the elevated ONS and 
inflammation observed in depressed subjects may partially be explained by inadequate dietary 
intake of antioxidants. 
Diet quality and mood: clinical trials 
Clinical trials investigating the efficacy of dietary interventions to treat depression, anxiety, and 
stress have reported improvements in mood and behavior, and beneficial changes in biological 
markers (See Table 1). A common characteristic among diets improving mood was high 
unsaturated fatty acid or fiber intake. 
The Mediterranean dietary pattern has been associated with a reduced risk of depression 
and has a low inflammatory potential (30–34). Recently, the Mediterranean diet with fish oil 
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supplementation (900 mg/d docosahexaenoic acid and 200 mg/day eicosapentaenoic acid) 
improved mental health and quality of life scores in subjects with depression (71). This 6-month 
dietary intervention prescribed daily consumption of fish oil capsules, bi-weekly workshops that 
instructed participants on how to prepare and cook meals adhering to the Mediterranean diet 
pattern, a supply of food items specific to the recipes discussed during the workshops, and 
additional food items including extra-virgin olive oil, vegetables, fruit, canned legumes, canned 
tomatoes, canned tuna, and mixed nuts. Following three months of treatment, participants no 
longer attended bi-weekly workshops, but continued consuming fish oil supplements until the 
end of the trial. The control group did not receive any training or fish oil capsules but did attend 
“social workshops” every two weeks. The social workshops consisted of various activities 
including playing games and book discussions, but did not include any nutrition or dietary advice 
or food items. Mental health outcomes were assessed by Depression, Anxiety, and Stress Scale 
(DASS) scores, Positive and Negative Affect Scale scores, and Assessment of Quality of Life-
8D scale scores. After three months of participation in the study, the Mediterranean diet and 
control group improved all outcomes from baseline. However, the Mediterranean diet group’s 
DASS - Depression subscale scores and Assessment of Quality of Life-Mental health scores 
showed a greater improvement over the course of the study compared to the control group (1.68 
and 1.52 times, respectively). No changes to outcomes from three months to six months were 
reported, despite similar Mediterranean diet scores between the two groups.  
Adherence to a diet to reduce depression symptoms and nutritional counseling reduced 
symptoms of depression in subjects with major depression (12). Jacka and colleagues utilized 
nutritional counseling to provide support for diet quality and improve Montgomery–Asberg 
Depression Rating scale scores. They reported reductions in depression symptoms following 
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personalized dietary support and counseling (12). The foundation of the treatment diet was 
modeled after the traditional Mediterranean diet, but also followed the recommendations of the 
Australian dietary guidelines and the Greek dietary guideline and was termed the “ModiMed” 
diet. For a thorough description of the ModiMed diet see reference (72). Briefly, the ModiMed 
diet recommended daily intakes of whole-grains (5-8 servings), vegetables (6 servings), fruits (3-
5 servings), reduced-fat and unsweetened dairy (2-3 servings), extra-virgin olive oil (60 mL), and 
nuts (1 serving) and weekly consumptions of legumes (3-4 servings), lean red meat (3-4 
servings), fish rich in oil (≥ 2 servings), poultry (2-3 servings), eggs (≤ 6 eggs), and limit 
additional foods to < 3, e.g., fast-food, sweets, 2 alcoholic beverages, etc. Notably, the ModiMed 
diet provided > 20% of total energy from monounsaturated fatty acids and daily dietary fiber 
intake was approximately 50 g/day. The recommendation of 3-4 servings of lean red meat was 
substantiated by reports linking weekly intake of lean red meat outside the range of 3-4 servings 
to a greater likelihood of depressive and anxiety disorders and the richness of nutrients 
hypothesized to play a protective role in many mental illnesses, e.g., iron, zinc, and vitamin B12 
(72).  
Brinkworth et al. conducted a 1-year dietary intervention implementing a high 
carbohydrate/low-fat diet or a low carbohydrate/high-fat diet and reported reductions in Beck 
Depression Inventory scores and improvements to Profile of Mood States scores from both diets 
(73). The low carbohydrate/high-fat diet limited carbohydrates to 14% of total kilocalories and 
set the daily intake of fat at 58% of total energy; unsaturated fatty acids comprised 51% (38% 
monounsaturated fatty acids; 13% polyunsaturated fat (PUFA)) of this group’s diet. Diets rich in 
unsaturated fatty acids, especially long-chain PUFAs may have antidepressant effects on 
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depressed individuals (39,40). Similarly, the high carbohydrate/low-fat diet group’s fat 
consumption was primarily comprised of unsaturated fatty acids.  
Similar results were reported in a clinical trial that investigated the effect of saturated 
fatty acid:unsaturated fatty acid ratio on mood and behavior (74). The saturated fatty acid, 
palmitic acid, and monounsaturated fatty acid, oleic acid, were given to participants at a ratio of 
either high palmitic acid:low oleic acid or high oleic acid:low palmitic acid. All food was 
provided to the subjects during the intervention (74). Utilizing the Profile of Mood States 
questionnaire, Kien et al. reported a reduction in subscale scores related to anger-hostility among 
subjects receiving high oleic acid compared to high palmitic acid treatment. In men, high oleic 
acid treatment corresponded with a decrease in total mood disturbance.  
The supplementation of omega-3-PUFAs may also confer mental health benefits, 
although mixed results have been reported (75,76). Kiecolt-Glaser and colleagues compared 
omega-3 PUFAs to a placebo mimicking the saturated:monounsaturated:polyunsaturated fatty 
acid ratio consumed by US adults. Compared to controls, subjects in the treatment group 
exhibited a 14% reduction in lipopolysaccharide-stimulated pro-inflammatory cytokine 
interleukin-6 (IL-6) and a 20% reduction in anxiety symptoms. Additionally, they reported n-6 
PUFA:n-3 PUFA ratio as a slightly stronger predictor of anxiety scores and lipopolysaccharide-
stimulated IL-6 production with increasing n-6 PUFA:n-3 PUFA ratio associated with increased 
anxiety scores and lipopolysaccharide-stimulated IL-6 production (75). 
In 2016, Breymeyer et al. reported differences in mood between a high-glycemic load 
diet and low-glycemic load diet (77). The dietary fiber content of the low-glycemic load diet and 
high-glycemic load diet were 55 g/day and 28 g/day, respectively (77,78). The investigators 
reported lower mean vigor/activity scores, a subscale of the Profile of Mood States 
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questionnaire, during the high-glycemic load diet compared to the low-glycemic load diet. 
Moreover, participants consuming a high-glycemic load diet reported higher Profile of Mood 
States subscale scores, fatigue/inertia and total mood disturbance, indicative of lower subjective 
energy and less mood stability. Clinical Epidemiological Studies Depression Scale scores were 
38% higher when a high-glycemic load diet was consumed compared to when a low-glycemic 
load diet was consumed (77). The results suggest glycemic load impacts subjective mood. 
Specifically, high-glycemic load diets may decrease subjective energy perception, while 
reducing mood stability. 
The improvement in Beck Depression Inventory scores and total mood disturbance scores 
may be related to the high unsaturated fatty acid content of the treatments (73,74). Unsaturated 
fatty acids may improve depression symptoms by reducing systemic inflammation (79). 
Unsaturated fatty acids are involved in multiple signaling pathways, and their inhibition of pro-
inflammatory cytokines may be related to the therapeutic effects exerted by unsaturated fatty 
acid consumption (76,80). Individuals with depression have been shown to have high 
concentrations of circulating pro-inflammatory cytokines (81).  Additionally, saturated fatty 
acids can elicit an inflammatory response by acting on pro-inflammatory receptors, e.g., toll-like 
receptor 4 (82).  
Dietary fat intake can also influence the gastrointestinal microbiota and inflammation, see 
reference (83) for a more thorough review. Briefly, dietary fat intake stimulates the secretion of 
bile acids. Bile acids that reach the large intestine have an antimicrobial effect on resident 
microbes. Gram-negative bacteria, a primary source of lipopolysaccharides, tend to be more 
tolerant of bile acids compared to gram-positive bacteria. Thus, high dietary fat intake may 
reduce total bacterial numbers in the large intestine (84), while the proportion of gram-negative 
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bacteria are enhanced, increasing a major source of lipopolysaccharides. However, it is important 
to note that the direct effect dietary fats have on the gut microbiota is still not well known, 
largely due to the incorporation of fat at the expense of carbohydrates, a major source of energy 
for microbes, in study diets.  
The evidence provided from clinical trials suggests diet quality impacts mood. It should 
also bring attention to dietary fiber and n-3-PUFAs consumption. The relationship between fiber 
and mood is less explored than n-3-PUFAs. However, both may improve mood by reducing 
systemic inflammation. Intervention trials are needed to determine if fiber consumption 
contributes to changes in mood and if the food source of fiber or the isolated fiber by itself 
affects mood.  
Prebiotic fibers and gastrointestinal microbiota 
A prebiotic is a substrate that is selectively utilized by host microorganisms conferring a health 
benefit to the host (85). Most prebiotics are fibers, however, it is not a prerequisite for being 
considered a prebiotic. As research continues, it is likely that additional dietary components, 
such as polyphenols, may be recognized as prebiotics (85). Prebiotics are present within foods, 
i.e., onions, chicory root, and wheat, or taken in a purified form as a dietary supplement. 
Prebiotics may attenuate disease by promoting the growth of beneficial microbes and/or reducing 
pathogenic microbes (9,86,87). Prebiotics have demonstrated psychobiotic effects in human 
clinical trials. Psychobiotic describes a bacteria or source of support for bacteria that beneficially 
affects the relationship between the microbiota and brain (88). Commonly studied prebiotics for 
mood and behavior improvement include fructooligosaccharides and galactooligosaccharides 
(89). Both prebiotics have demonstrated the ability to enhance Bifidobacterium in humans (9,90–
92). Although, the bifidogenic effect may be dose-dependent, requiring > 5.0 g/day to enhance 
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bifidobacteria (93–95). Bifidobacteria may promote health benefits by producing B vitamins, 
antioxidants, and polyphenols (96,97); and aiding immune system function by inducing the 
production of immunoglobulins (49,97). Additionally, bifidobacteria contribute to the production 
of lactate and acetate, which can be utilized by other bacteria in the gastrointestinal microbial 
community to produce butyrate, a phenomenon known as cross-feeding (98). This production of 
SCFA also provides a benefit to the host by suppressing pathogenic microbes by the inherent 
decrease in pH with increasing SCFA concentrations. (98,99). 
Prebiotics and mood: clinical trials 
Three randomized controlled trials (Table 2) reported improvements in mood or behavior 
following the administration of prebiotic fibers, fructooligosaccharides, galactooligosaccharides, 
or trans-galactooligosaccharides (15,100,101). Fructooligosaccharides and trans-
galactooligosaccharides supplemented at 5.0 g/day and 7.0 g/day, respectively, induced changes 
to the gastrointestinal microbiota, along with improvements in mood (15,101). 
Silk et al. examined the ability of trans-galactooligosaccharide to relieve symptoms of 
irritable bowel syndrome and improve mood (15). Patients receiving 7.0 g/day of trans-
galactooligosaccharide reported significantly lower scores on the Hospital Anxiety and 
Depression Scale-Anxiety subscale compared to baseline. Trans-galactooligosaccharide 
enhanced Bifidobacterium spp. and reduced Clostridium perfringens subgroup histolyticum, 
Bacteroides/Prevotella ratio, and Eubacterium rectale/Clostridium coccoides.  
Similar results have been reported following fructooligosaccharide consumption. A study 
investigating the efficacy of 5 g/day fructooligosaccharide to treat irritable bowel syndrome 
symptoms reported a decrease in Hospital Anxiety and Depression Scale-Anxiety subscale 
scores (101). Moreover, fructooligosaccharide consumption increased fecal bifidobacteria.  
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In 2015, Schmidt et al. assessed the effects of Bimuno® galactooligosaccharide and 
fructooligosaccharides on salivary cortisol levels and emotional processing (100). They reported 
anxiolytic-like effects and decreased waking salivary cortisol concentrations and attentional 
vigilance to negative versus positive stimuli in subjects receiving Bimuno® 
galactooligosaccharide treatment. No differences in salivary cortisol were reported for the 
fructooligosaccharide treatment (100).  
The anxiolytic and antidepressant effects demonstrated in these trials are not well-
understood and additional studies are needed to confirm the anxiolytic and anti-depressant 
effects of specific prebiotics. One explanation for the changes in mood may be related to the 
bifidogenic effect from fructooligosaccharide and galactooligosaccharide supplementation. 
Prebiotics fermented by microbes in the gastrointestinal tract produce metabolites, like SCFA, 
that may enhance and help regulate immune system function (102,103). Dysregulation of the 
immune system may disrupt homeostasis, altering critical feedback mechanism, e.g., cortisol 
production.  
Cortisol, a glucocorticoid hormone, has widespread effects and is involved in several 
mechanisms of homeostasis and adaption to stressors, such as glucose metabolism, immune 
system regulation, and inflammation. A key regulator of cortisol production is the hypothalamic-
pituitary-adrenal (HPA) axis (104). The hypothalamic-pituitary-adrenal axis primarily regulates 
cortisol output through negative feedback mechanisms, but stressors, e.g., inflammation and 
psychological stress, can bypass these control mechanisms and increase hypothalamic-pituitary-
adrenal axis activity resulting in increased cortisol production. Chronic exposure to stressors 
cause over-suppression of the immune system, increased circulating pro-inflammatory cytokines, 
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and increased risk of developing anxiety and depression (104,105). Gastrointestinal microbiota 
may mediate HPA activity by modulating immune responses to stressors (106).  
Probiotics and mood 
Probiotics, defined as live microorganisms that when consumed in adequate amounts confer 
health benefits to the host (107), have demonstrated benefits to mental health (Table 2). 
Probiotics are inherent in many fermented foods, e.g., yogurt, sauerkraut, and kefir, and are 
commercially available as dietary supplements. Probiotic consumption can promote 
gastrointestinal microbiome functions, including inhibition of pathogenic species, epithelial 
barrier integrity, and modulation of immune response (108,109). Probiotics, specifically, 
Lactobacillus spp. and Bifidobacterium spp. are typically representative of only a small 
proportion of the human gastrointestinal microbial community but have been associated with 
improvements in mental health. A probiotic strain may affect mood by direct or indirect 
interaction with the central nervous system, modulation of immune response, and inhibition of 
opportunistic pathogens (110).  
Gastrointestinal microbes can interact with the central nervous system directly or 
indirectly through the synthesis of neurotransmitters, e.g., serotonin, and metabolites that interact 
with hormone receptors in the large intestine; SCFA activate GPR43 on L-cells stimulating the 
release of glucagon-like peptide-1. Serotonin and its precursor, tryptophan, can be produced by 
microbes in the gastrointestinal tract and may influence the concentration of serotonin in the 
brain (111,112).  Low levels of serotonin in the brain have been associated with depressed mood. 
The influence microbially derived neurotransmitters have on psychophysiology is still being 
researched, but modulation of neurotransmission of the enteric nervous system may contribute to 
the release of gut hormones linked to mood and behavior (88).  
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Probiotics and mood: clinical trials 
Studies investigating the effect of single-strain probiotics on mood have reported improvements 
in humans, Table 3. For example, Bifidobacterium longum species may promote improvements 
in mental health. B. longum strains have been shown to reduce stress (113) and depression scores 
(114). Additionally, Messaoudi and colleagues reported decreased Hospital Anxiety and 
Depression Scale scores in participants consuming a probiotic comprised of B. longum R0175 
and Lactobacillus helveticus R0052 (115).  
Clinical trials investigating L. casei Shirota have reported reductions in anxiety scores 
(116) and biomarkers of stress in subjects consuming the probiotic (117,118). L. casei Shirota 
consumption reduced anxiety scores in individuals suffering from chronic fatigue syndrome. In a 
cohort of medical students preparing for an exam, where self-reported stress increased as the 
exam approached, consumption of L. casei Shirota suppressed stress-response genes. 
Additionally, salivary cortisol was elevated in the placebo-treatment, but not in subjects 
consuming probiotic-treatment, as the exam approached. However, these findings were not 
replicated in healthy individuals. Benton et al. reported null findings following the consumption 
of a milk-drink containing L. casei Shirota in healthy adults. Thus, L. casei Shirota may suppress 
stress and anxiety rather than reducing it (116–119). 
It is also important to note that the probiotic effects of bacteria are strain dependent. For 
example, two different strains of Lactobaccilus, L. rhamnosus JB-1 and L. rhamnosus HN001, 
were used in separate studies. Kelly and colleagues administered L. rhamnosus JB-1 to healthy 
adult men and women and reported no differences in physiological or psychological measures of 
stress (120). Conversely, women consuming L. rhamnosus HN001 from ~15 weeks gestation to 
6 months postpartum reported lower depression and anxiety scores compared to placebo (121).  
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Multi-strain probiotics have also demonstrated the ability to improve mood (see Table 3) 
in healthy (115,122–124) and diseased (125) populations. Although many of the multi-strain 
probiotics improved mood, outcome measurements were not consistent when probiotics 
containing the same species of bacteria were consumed. For example, Steenberg et al. 
investigated a probiotic containing B. bifidum, L. acidophilus, and L. casei among others, and 
reported no changes to Beck Depression Inventory scores (123). Contrarily, Akkakesh et al. 
reported a reduction in Beck Depression Inventory scores following the consumption of a 
probiotic containing the same three bacterial species (125). These conflicting results may 
partially be explained by the differences in study populations, as Akkakesh and colleagues 
studied the probiotics affect on subjects suffering from major depressive disorder. Moreover, the 
dose of probiotic administered in the study conducted by Steenberg et al was lower than the dose 
prescribed by Akkakesh et al. To fully understand the effects probiotics have on mood, 
additional intervention studies need to be conducted in healthy and diseased populations and the 
prescribed dosages of the probiotic and strain should be similar to past studies. 
Limitations of clinical trials  
Diet quality  
A limitation of dietary trials is that adherence to a prescribed dietary pattern is frequently 
measured by self-reported diet-records or self-reported questionnaires. Self-reported diet records 
may not accurately reflect the amount of food consumed by a participant resulting in under- or 
overestimated values. It is also not always possible, or is very difficult, to blind participants 
and/or researchers to nutritional treatments, which may bias results. In addition, the impact 
dietary changes have on the gastrointestinal microbiota was not measured by any of the clinical 
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trials investigating diet quality and mood in this review. Thus, we can only speculate on the role 
gastrointestinal microbiota played in the mood and behavioral changes. 
Prebiotics 
Fructooligosaccharides and galactooligosaccharides demonstrated anxiolytic effects when 5.0 
g/day or more was consumed. However, only one study was conducted in healthy adults (100). 
The other two studies reported findings from patients with irritable bowel syndrome (15,101). 
Many of the trials reviewed also lacked participant dietary information. Additional studies in 
healthy populations are needed to translate these results to the general population. 
Probiotics 
A majority of the studies investigating the effects of probiotics on mood and behavior reported 
improvements. However, few studies analyzed the gastrointestinal microbiota. Also, to better 
understand an individual strain’s therapeutic effect, additional studies with single strain 
probiotics need to be conducted as the utility of a probiotic may depend on the strain. 
Investigating the gastrointestinal microbiota will also provide insight into the adaptions 
occurring in the gastrointestinal ecosystem following probiotic consumption. Microbiota 
analyses may help differentiate responders versus non-responders to probiotic treatment in future 
studies. 
Summary of findings 
Consumption of high-quality diets reduced depression, anxiety, and stress symptoms in clinical 
trials, especially when intervention diets were rich in n-3-PUFAs and fiber (73,78). Furthermore, 
fiber from fruits and vegetables was associated with reduced likelihood of depression symptoms, 
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irrespective of total fiber intake (47). This may partially be explained by the high concentrations 
of antioxidants within fruits. Fiber and antioxidants may synergistically benefit gut health by 
enriching bifidobacteria and reducing inflammation. 
Galactooligosaccharide and fructooligosaccharide consumption had anxiolytic and anti-
depressive effects on subjects with irritable bowel syndrome (15,101). When they were 
administered to healthy women, galactooligosaccharides induced anxiolytic effects in the 
participants. Notably, a reduction in waking cortisol was reported in a healthy cohort of women, 
but no significant reduction in anxiety scores was observed in self-reported questionnaires (100). 
Although specific prebiotics have displayed psychobiotic properties, due to the very limited 
evidence available, additional clinical intervention studies are needed before they can be 
accepted as anxiolytic or anti-depressive. 
The clinical trials investigating probiotics revealed certain probiotics were efficacious as 
therapeutic agents for the treatment of depression, anxiety, and stress. Both physiological 
biomarkers and psychological symptoms were relieved or suppressed following the consumption 
of probiotics. Specifically, B. longum and L. casei Shirota may have therapeutic effects for 
individuals suffering from mood disorders.  
Conclusions 
Reports from dietary interventions provide evidence that there is a link between diet quality and 
mood. Yet, the directionality of these relationships still needs to be discerned. To accomplish 
this, longitudinal studies and clinical trials need to be conducted and biological markers of 
disease need to be recorded. The efficacy of prebiotics to treat mood disorders is less certain due 
to a paucity of studies investigating prebiotics effect on mood. Regarding the gastrointestinal 
microbiota, altered microbiota composition has been reported in depressed individuals (20) and 
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specific microbes have been associated with depression (21), but an insufficient amount of 
clinical data is currently available to causatively link the gastrointestinal microbiota to 
depression, anxiety, and stress in humans. Additional well-designed dietary intervention trials 
targeting the interconnection of diet quality, dietary components, and the gastrointestinal 
microbiota are required. Identifying the microbial species residing in the gastrointestinal tract 
will help progress our understanding of their involvement in mood disorders. Nevertheless, 
microbiota compositional data has a limited capacity to characterize microbiome functionality. 
Thus, additional multi-omics technologies are needed to develop an understanding of 
mechanisms and pathways the microbiota may alter.  
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CHAPTER 2: Associations among diet, the gastrointestinal microbiota, and negative 
emotional states in adults 
Abstract 
Objective: Habitual diet impacts mood and plays a role in shaping the composition and 
function of the human gastrointestinal (GI) microbiota. Yet, studies infrequently control for 
dietary factors when evaluating associations between mood and GI microbiota. We 
hypothesized that relationships exist between GI microbes and mood, even after 
incorporating dietary fiber in the analyses.  We also hypothesized that fiber intake and diet 
quality scores would be inversely related to negative emotional states. 
Methods: Adults (N=133; 25-45 years of age) without physician diagnosed mood 
disorders were included in the study. Fecal DNA was extracted, sequenced, and then 
analyzed using QIIME2 to characterize the GI microbiota. Subjective mood state was 
assessed using the 42-item Depression, Anxiety, and Stress Scale (DASS-42). Habitual 
dietary intake was measured with the National Cancer Institute’s Diet History 
Questionnaire II, and diet quality was evaluated with the 2010 Healthy Eating Index (HEI).  
Results: Relationships were observed between 28 bacterial taxa and DASS-42 scores. Sex-
dependent associations were observed among 21 bacterial taxa and DASS-42 scores 
including an inverse relationship between Anxiety scale scores and Bifidobacterium in 
female participants. HEI total fruit and dairy components were inversely associated with 
Depression and Stress scales, respectively. 
Conclusions: These results suggest GI microbes are related to mood in adults without 
diagnosed mood disorders and the relationships differ by sex and are influenced by dietary 
fiber intake. Incorporating dietary intake data in gut-microbiota-brain studies may help 





The mood disorders depression and anxiety affect an estimated 4.7% and 7.3% of the global 
population, respectively (126,127) and individuals with mood disorders have a mortality rate 
two-times greater than the general public (128). Accumulating evidence indicates that the 
gastrointestinal (GI) microbiota may contribute to mood disorders. The GI microbiota is thought 
to influence behavior through the gut-brain axis, a bidirectional communication network between 
the central nervous system and GI tract (88). The GI microbiota may alter hormonal, neural, or 
immune pathways that maintain homeostasis and allow communication along the gut-brain axis 
(88).  
Preclinical and clinical studies have revealed a role for GI microbiota in mood disorders. 
Germ-free mice have an enhanced physiological responses to stress compared to pathogen-free 
mice and the altered stress response can partially be corrected if GI microbiota are reconstituted 
at an early age (18). Interestingly, a depressive behavioral phenotype was transferred to 
microbiota-deficient rats following a fecal microbiota transplant from participants with 
depression (19,20). Findings from these studies indicate that the GI microbiota is linked to 
physiological mechanisms related to stress and that the GI microbiota can influence behavior. 
Clinical studies also suggest that the GI microbiota is altered in individuals with mood disorders 
(17,19–21,129). Differences between the GI microbiota of subjects with depression and controls 
have been observed, as have sex differences in the GI microbiota of male and female participants 
with depression (17,20,21,129). Furthermore, probiotic consumption has improved mood in 
clinical and healthy populations, indicating that certain bacterial strains may benefit mood (130).  
The findings from preclinical and clinical studies, while limited, are promising; however, 
the role of GI microbiota in mood disorders is still unclear. Currently, there is no consensus on 
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the representation of altered bacterial taxa in individuals with depression, as previous findings 
have conflicted (17,20). For example, compared to controls, the GI microbiota of subjects with 
depression had an overrepresentation of Bacteroidetes in one study (7), but a similar case-control 
study reported an underrepresentation of Bacteroidetes in participants with depression (17,20). 
Although, neither study examined the relationship between the different subtypes of depression. 
The uncertainty extends to populations without depressive symptoms as well. A recent study by 
Kleiman and colleagues reported no statistically significant relationships between mood and GI 
microbiota in women without psychological disorders (131).  
Differences in dietary intake patterns may partially explain the contrary or null findings, 
as none of these studies accounted for habitual diet (17,20,131). GI microbiota composition is 
effected by diet and dietary fiber consumption (7,51). Dietary intake patterns are also associated 
with mood. Dietary patterns characterized by high intake of fruits and vegetables, whole grains, 
fish, and olive oil may decrease the risk of depression (25). These food groups are also rich 
sources of nutrients, e.g. dietary fiber, that can be fermented by GI microbes (51). The influence 
diet has on mood and GI microbiota composition requires the use of dietary intake records or 
interventions to better understand the relationships between GI microbiota and mood. 
Accordingly, we aimed to investigate relationships among diet, GI microbiota, and mood 
in adults without mood disorders by conducting a cross-sectional examination of dietary intake, 
subjective emotional state, and fecal microbial taxa abundances. This study tests the hypotheses 
that depression, anxiety, and stress symptoms are related to GI microbes and that these negative 
emotional states are inversely related to diet quality and dietary fiber. Moreover, by focusing the 
analyses on GI microbes previously linked to depression, anxiety, or stress in preclinical studies, 
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as well as clinical studies of populations with mood disorders, this study attempts to determine if 
the results of previous reports translate to adults without mood disorders.  
Methods 
Subjects 
Participants were recruited from the University of Illinois and the surrounding area via flyers, e-
mails, and by contacting participants from prior studies that consented to be contacted. 
Participants between 25-45 years of age with a body mass index (BMI) ≥ 18.5 kg/m2 were 
included in the study. Study exclusion criteria included prior physician diagnosed metabolic or 
GI disease, diagnosed cognitive or physical disability, use of medications that alter bowel 
function and metabolism, food allergies, pregnancy, or lactation. All participants were informed 
of the study’s purpose, the experimental procedures, and the risks of each experimental 
procedure. Each individual provided written informed consent prior to enrollment in the study. 
The study received written approval by the University of Illinois Institutional Review Board. 
Measures 
Anthropometric measurements 
Body weight and height were measured using a stadiometer (Seca; model 240) and a digital scale 
(Tanit; WB-300 Plus), respectively. The averages of three measurements of body weight and 
height were recorded then used to calculate BMI (weight in kilograms/[height in meters]2). 
Habitual diet and diet quality 
Habitual dietary intakes were quantified using the National Cancer Institute’s (NCI) Diet History 
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Questionnaire II with portion sizes. The Diet History Questionnaire II is a self-report food 
frequency questionnaire consisting of 142 items. Data generated from the questionnaire were 
analyzed by Diet*Calc, version 1.5 to quantify nutrient values. Diet quality was measured 
according to the 2010 HEI using NCI macros analyzed in SAS version 9.4. HEI values represent 
adherence to the 2010 Dietary Guidelines for Americans with scores of 0 and 100 indicating the 
lowest and highest adherence, respectively (132). Twelve components were used to generate a 
total HEI score, and each component represented a recommendation, in servings per 1000 kcals, 
from the Dietary Guidelines for Americans (132).  
Depression, Anxiety, and Stress Scales 
Participant’s subjective mood states were assessed using the self-report DASS-42, which has 
been validated in non-clincal samples (133). The DASS-42 consists of three scales, 14-items 
each, that measure the emotional states of depression, anxiety, and stress anchored within the 
week before the test (134). Responses were in the form of 4-point rating/frequency scales, 
ranging from 0 (did not apply) to 3 (applied most of the time). Each subscale measures the 
severity of the core symptoms of depression, anxiety, or stress to allow for discrimination 
between the three scales. The depression subscale focuses on dismal mood, motivation, and self-
esteem; the anxiety subscale focuses on autonomic arousal, subjective experience of panic, and 
fear; and the stress subscale focuses on strain and irritability (134). Responses were summed to 
generate scores for each emotional state subscale, and total DASS-42 score was calculated by 
summing the total score.  
Analysis of GI microbiota 
Fecal samples were received within 15 minutes of defecation and processed immediately upon 
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arrival. All samples were homogenized, aliquoted, snap-frozen in liquid nitrogen, then stored at  
-80°C until further analysis. Microbial DNA was extracted using Powerlyzer Powersoil Kit using 
the standard protocol (MoBIO Laboratories). After extraction, a 250-bp region from the V4 
region of the 16S rRNA gene was amplified according to Caporaso et al. using a Fluidigm 
Access Array (135). Sequencing was performed at the W.M. Keck Center for Biotechnology at 
the University of Illinois by using an Illumina MiSeq2000 with the use of v3 reagents (Illumina 
Inc.), as previously described (136). Microbial sequence data were analyzed with QIIME 2.1.12. 
Sequencing reads were denoised and clustered into amplicon sequence variatants using DADA2 
(137). Sequence variants were taxonomically classified against greengenes 13_8 99% OTU 
reference sequences. Alpha diversity (Shannon Index and Phylogenetic diversity) and beta 
diversity (weighted UniFrac) were calculated at an even sampling depth of 12,383 sequences per 
sample and used to assess differences in microbial diversity between male and female 
participants. 
Statistical Analysis 
Statistical analyses were conducted using Statistical Analysis Software version 9.4 and QIIME2. 
An alpha-value of ≤ 0.05 was considered statistically significant and was not adjusted for 
multiple testing because this is a preliminary study (138). Mixed modeling (PROC GLIMMIX) 
was used to model data. All selected models were based on best fit—the  ratio of chi-square to its 
degrees of freedom was used to analyze model fit and a value less than two indicated appropriate 
model fit (11). Each DASS-42 scale was tested separately, and their distributions were assessed 
to identify the best-fitting model (11). For the depression, anxiety, and stress subscale analyses, 
participants were excluded from the analyses if they did not complete all of the questions within 
the respective subscale.  For the total DASS score analyses, the mean for the respective question 
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that was not completed was imputed (n=14) to allow for calculation of a total score. Analyses 
were conducted on the entire cohort as well as separated by sex because males and females have 
been reported to differentially experience depression, anxiety, and stress symptoms (126). Age 
and BMI were controlled within all statistical models due to their influence on mood and GI 
microbiota (11,139,140). Each DASS scale was treated as a response variable and each dietary 
intake variable or bacteria variable was analyzed as an explanatory variable. Standardized dietary 
fiber (grams of total dietary fiber per 1000 kcal) was added to the bacterial model to account for 
variations in dietary fiber intake. Bacterial taxa were selected for analyses based on previously 
reported associations to depression, anxiety, or stress in preclinical or clinical studies conducted 
in populations with depression, anxiety, or stress (17,19–21,141). Results of the generalized 
linear mixed models are reported as parameter estimates, standard errors, and 95% confidence 
intervals of the fixed effects of the models in Tables 5-6 and Supplemental Table 1-4. 
Additionally, results are reported as standardized beta-coefficients and standard errors in 
Supplemental Tables 7-8.  
 
Results 
A total of 133 adults (n=60 males) were included in the study. A description of the population is 
presented in Table 4 and Supplemental Table 5. Briefly, several dietary intake variables 
differed by sex including daily intake of energy, protein, fat, and standardized dietary fiber 
(Table 4). Anxiety and stress subscale scores did not differ by sex. The depression scale score 
was greater in males compared to females. The mean for each subscale was within the normal 
range of symptom severity are consistant with the intended inclusion of participants without 
physician diagnosed depression, anxiety, or stress disorders. 
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Following quality filtering, a total of 4,113,997 sequences were retained with a mean and 
standard deviation of 30,932 ± 6,838 sequences per sample and range of 12,383 – 46,949. The 
mean relative abundances of taxa are presented in Supplemental Table 6. Samples were rarefied 
at an even sampling depth of 12,383 to estimate bacterial alpha diversity and beta diversity. No 
significant differences in alpha diversity or beta diversity were observed between male and 
female participants.   
Associations between diet quality and mood 
Associations among DASS-42 scores and dietary components are presented in Supplemental 
Tables 3-4. Two measures of diet quality correlated with mood. Stress scale scores were 
inversely associated with the HEI dairy component (p=0.02) among all participants and 
Depression scale scores were inversely related to the HEI total fruit component (p=0.04) among 
males. 
Relationships between mood and bacteria 
Associations between five bacterial variables and DASS-42 scores were observed when dietary 
fiber was not included in the statistical model. These data are presented in Supplemental Table 
1. Briefly, DASS-42 scores were positively associated with Enterobacteriaceae (depression), 
Peptostreptococcaeae (anxiety), and Butyricimonas (stress) and inversely associated with 
Porphyromonadaceae (anxiety) and Parabacteroides (anxiety).  
Peptostreptococcaeae remained statistically significantly associated with stress scale 
scores after dietary fiber was included in the statistical model (Table 5). Additionally, three 
bacteria were associated with DASS scores among the study sample—DASS-42 scores were 
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inversely associated with Anaerostipes (depression), Porphyromonadaceae (stress and Total 
DASS), and Parabacteroides (stress and Total DASS).  
Sex-dependent relationships 
Analyses by sex revealed DASS-42 scores were associated with nine bacterial variables in 
women and six in men (Supplemental Table 2). Among women, Paraprevotella (depression 
and anxiety), Dialister (anxiety and total DASS), Lactobacillaceae (anxiety), Lactobacillus 
(anxiety), Bacteroidaceae (stress), and Bacteroides (stress) were positively associated with 
DASS scores and inverse relationships were observed between DASS scores and Proteobacteria 
(stress and total DASS), Anaerostipes (depression), and Parabacteroides (anxiety).  
Among male participants, Phascolarctobacterium (anxiety) and Butyricimonas (stress) 
were positively associated with DASS-42 scores. Negative associations were observed among 
DASS-42 scores and Dorea (depression and anxiety), Rikenellaceae (depression), Ruminococcus 
(depression), and Blautia (anxiety).  
Table 6 includes sex-dependent relationships between mood and bacteria after dietary 
fiber was included in the statistical model. DASS-42 scores were related to 10 bacterial variables 
in females, and 11 in males. In females, Proteobacteria, Paraprevotella, and Dialister, remained 
statistically significant with their respective scale from the previous model. In males, 
Rikenellaceae, Dorea, and Blautia, maintained statistical significance.  
To estimate the effect size of the independent variable in the model, standardized coefficients of 
the fixed were calculated for the model accounting for dietary fiber and are presented in 




Summary of main findings 
This cross-sectional study investigated relationships between GI microbiota and mood among 
adults without diagnosed mood disorders. We observed that connections between mood and the 
GI microbiota are impacted both by participant sex and dietary fiber intake. The hypothesized 
associations between diet quality and mood were partially observed—higher HEI total fruit 
scores were inversely associated with depression subscale scores in male participants.  
Contrary to our hypotheses, we did not observe statistically significant relationships 
between dietary fiber and mood. However, we did observe that increased adherence to the HEI 
recommendations for total fruit were related to lower depressive symptom scores. Our study did 
not discriminate by source of dietary fiber, which may be important for consideration in future 
studies. A study led by Miki et al. reported dietary fiber from fruits and vegetables, but not 
soluble, insoluble, or total dietary fiber, was associated with a reduced risk of depressive 
symptoms (47). Further, low fruit consumption has been associated with a higher risk of 
depressive symptoms (46). Fruits are rich sources of nutrients that impact the GI microbiota, 
including dietary fiber and phytonutrients. Dietary fiber and phytonutrients can modulate the GI 
microbiota, typically by increasing Bifidobacterium (142).  
Our results indicate that Enterobacteriaceae is associated with DASS-42-Depression 
scores when dietary fiber is not included in the model, concordant with a previous report of this 
taxa being overrepresented in subjects with depression (20). In the large intestine, dietary fiber 
can be metabolized by microbes to produce short-chain fatty acids. An increase in short-chain 
fatty acid concentrations reduces the intestinal pH and consequently inhibits the growth of 
Enterobacteriaceae (11,143). Thus, low dietary fiber intake may create an environment 
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conducive to Enterobacteriaceae growth due to lower short-chain fatty acid concentrations and a 
higher luminal pH. However, since our analyses did not include short-chain fatty acids and the 
previous study (20) relating Enterobacteriaceae to depression did not account for dietary fiber 
intake, additional investigations are warranted to clarify the relationship between 
Enterobacteriaceae and depression. 
A previous study by Zheng et al. reported Anaerostipes was overrepresented in subjects 
with depression (17). Contrarily, our results revealed Anaerostipes was inversely related to 
depression scores, i.e, a larger relative abundance of Anaerostipes was associated with lower 
depression subscale scores. Aside from mental health status, differences in directionality 
between results from this report and previous studies may be related to geographic location. This 
study was conducted in the US, whereas the study conducted by Zheng et al. was conducted in 
China. The differences in dietary patterns between the US and China may differentially influence 
GI microbiota composition. For example, Zheng et al. describe the participants’ diets as being 
dominated by rice and small amounts of meats and vegetables. In our study, a variety of different 
diets were consumed. Thus, nutrient intakes between our study and Zheng et al. were likely 
considerably different. 
Our results indicate that the relative abundances of Peptostreptococcaeae increased 
alongside anxiety symptoms. Studies investigating altered GI microbiota in individuals with 
anxiety disorders are lacking. Although, a recent study reported that neuroticism, a personality 
trait associated with an increased risk of anxiety disorders, was positively associated with 
Peptostreptococcaeae (144). Preclinical, and to a lesser extent clinical, studies have shown that 
chronic stress may induce anxiety-like behavior and changes to the composition of the GI 
microbiota (141,145).  
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Gender-specific relationships between GI microbiota and mood were observed in this 
study. Coriobacteriaceae and Dialister were positively related to depression scores among 
women. Two recent studies reported greater relative abundances of Coriobacteriaceae (129) and 
Dialister (146) among women with depression as compared to healthy controls.  
Lactobacillus spp. and Bifidobacterium spp. are considered psychobiotic species due to 
their mood enhancement properties. Psychobiotics are bacteria, or sources of support for 
bacteria, that positively influence the gut-brain axis (88). In our study, Lactobacillus was 
inversely associated with depression scores among males, findings that agree with clinical trials 
showing reduced depressive symptoms with Lactobacillus spp. supplementation (130). We also 
observed an inverse relationship between anxiety scores and Bifidobacterium among females. A 
recent meta-analysis reported that there is inadequate evidence to support Bifidobacterium spp. 
as anxiolytic bacteria (147). However, a clinical trial reported that fermented milk containing B. 
animalis reduced responsiveness to negative emotional stimuli in healthy participants, suggesting 
that psychobiotic-containing fermented milk may suppress reactivity to negative stimuli, which 
may benefit anxious individuals (122). Overall, a paucity of clinical studies have investigated GI 
microbiota composition in anxious individuals, and further investigation is needed to connect the 
contributions of specific bacterial strains to anxiety symptoms. 
We observed an inverse relationship between Roseburia and stress scores among men. 
Similarly, a stress-induced reduction in Roseburia was previously reported in a predominantly 
male (97%) sample (145). Establishing connections between stress and GI microbiota 
composition may help determine the directionality and causal role of GI microbiota in other 
mood disorders. Chronic physiological stress and/or psychological stress may promote 
alterations in neural and hormonal regulatory systems, observed in mood disorders. However, it 
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is not yet known if the GI microbiota influences these systems or if these systems influence the 
GI microbiota in humans. 
Herein, the relations between the severity of symptoms of depression, anxiety, and stress, 
as assessed by the DASS-42 questionnaire, and GI microbes were assessed. It is important to 
note that the subjective symptoms queried in the DASS-42 questionnaire differ from other scales 
used to assess negative mood. Therefore, the relationships reported in this study may differ from 
other studies that utilized different instruments. For example, Hamilton’s Depression Scale is a 
depression rating scale that primarily focuses on the physical symptoms of depression, including 
insomnia, weight loss, somatic gastrointestinal symptoms, and somatic symptoms of anxiety. On 
the contrary, the Beck Depression Inventory (BDI) primarily focuses on the cognitive symptoms 
of depression. Interestingly, BDI was used in a previous study conducted by Kleiman and 
colleagues and reported no associations between cognitive symptoms and GI bacteria (131) 
Therefore, future studies investigating relations between the gut-microbiota-brain axis should 
consider the utility of different scales and how the measured subjective symptoms are related to 
specific GI bacteria. 
Strengths and limitations 
The findings from this study do not designate the GI microbiota as a cause for DASS scores due 
to the cross-sectional design. Additionally, GI microbiota composition was used to identify 
relationships between bacteria and mood, but a functional analysis of GI microbiota (e.g. 
metabolites and RNA) was not conducted. Metatranscriptomic analyses and metagenomic 
sequencing analyses may help explain the relationships observed by identifying microbial genes 
associated with emotional states and should be included in future studies. Specific to dietary 
assessments, while this study utilized a validated dietary questionnaire to examine contributions 
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of habitual diet, including dietary fiber and HEI scores, to relations between the GI microbiota 
and mood, this instrument may not have been sensitive enough to discern specific contributions 
of micro- and macronutrient intakes. Therefore, future intervention studies that carefully measure 
and/or control for diet are necessary (148). In addition, as the study cohort was limited to 
individuals without physician diagnosed mood disorders, these results may not be generalizable 
to those with clinical mood disorders.    
Study strengths include the use of dietary intake records in conjunction with microbiota 
data. Accounting for the variation in dietary fiber intake provided a clearer representation of the 
relationships between mood and GI bacteria. This study analyzed data continuously and by 
gender allowing sex-dependent relationships between the severity of the core symptoms of 
depression, anxiety, and stress, as assessed by the DASS-42 questionnaire, to be measured. HEI 
was used to assess diet quality and has shown a superior utility in capturing variance among diets 
in microbiome studies conducted in Western populations (149). As the results reported herein are 
based on an analysis of adults without clinical depression, anxiety, or stress disorders, the 
findings are not limited to populations of adults with mood disorders and are generalizable to the 
larger adult population that experiences negative mood states at a subclinical level.   
Implications for future research 
This study related the GI microbiota to the subjective symptoms of depression, anxiety, and 
stress in a sample of healthy adults, without physician diagnosed mood disorders, and observed 
differences in these relationships by sex and dietary fiber intake. Additionally, diet quality 
measures were related to stress and depressive symptoms. Sex-specific relationships were 
observed in this study, findings consistent with previous studies that had male- or female- 
dominant samples (129,145). Findings from this study support the need to incorporate dietary 
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intake data when studying the microbiota-gut-brain axis (148).  It is important for future studies 
to incorporate measures of habitual diet into the study design to account for the influence diet has 
on the GI microbiota composition and decrease the difficulty of repeating analyses. Future 
studies should characterize GI microbiota in clinical populations, especially among individuals 
with anxiety and stress, to establish connections between specific microbes and mood. In 
depressed populations, characterizing and comparing compositional differences of the microbiota 
by depression subtype may reveal more discrete differences among subtypes. The tool used to 
assess depressive symptoms should also be considered in future studies because of the 
heterogenous nature of depression. Additionally, clinical intervention trials that modify dietary 
intake are needed to determine if dietary modulation of the GI microbiota effect mood among 
those with and without mood disorders. Determining the combined roles of diet and GI 
microbiota in mood disorders may lead to discovery of new dietary and/or microbial treatment 
options for individuals with these conditions and provide a better understanding of the etiology 






















CHAPTER 3: General discussion and conclusions 
In summary, dietary intake and the GI microbiota form an interconnected relationship 
with mood. This work reviewed and summarized previous studies that investigated the relations 
among diet, the GI microbiota, and the negative emotional states of depression, anxiety, and 
stress and introduced new findings that link diet and the GI microbiota to depression, anxiety, 
and stress.  
Additional studies related to the topic area have been published since the publication of 
the first chapter, which reviewed the literature. These new studies revealed findings that were not 
available at the time this work was written and contribute to this work by providing an update. 
The purpose of this section is to update this work by reviewing relevant new literature.  
A clinical trial orchestrated by Kazemi and colleagues, in April 2018, investigated the 
effects of probiotics and prebiotics on mood in individuals with major depressive disorder (150). 
The participants were randomly assigned to receive a probiotic, a prebiotic (4.8 g/day 
galactooligosacchrides), or a placebo treatment as an adjunct to their current treatment, for 8 
weeks. The probiotic treatment, containing Lactobacillus helveticus R0052 and Bifidobacterium 
longum R0175, demonstrated an anti-depressant effect, while the prebiotic and placebo 
treatments did not alter depression symptoms. The findings that L. helveticus R0052 and B. 
longum R0175 reduce depression symptoms were previously demonstrated in a non-clinical 
sample by Messaoudi et al. in 2011. Interestingly, Romijn and colleagues in a previous study, 
administered L. helveticus R0052 and B. longum R0175, as primary treatment for depression in a 
clinical sample and did not report any significant changes after 8 weeks of probiotic treatment 
(151). In context, probiotics alone may be beneficial to individuals without depression, but may 
also be used as an adjunct treatment to individuals with depression.  
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In June 2018, a meta-analysis conducted by Reis et al. investigated the anxiolytic effects 
of probiotics (147). The authors concluded that the available evidence suggests that probiotics do 
not significantly reduce symptoms of anxiety in humans. These conclusions were based on 
findings from 14 clinical trials. However, the authors extended caution to the interpretation of the 
results due to the substantial heterogeneity between studies. The authors also reflected on the 
high degree of variability among subject characteristics, outcome measures, probiotic strain, 
probiotic dose, and duration of treatment from study to study. The findings that probiotics are not 
an efficacious treatment for anxiety are still preliminary due to the dearth of relevant studies and 
the variability in methods among the studies analysed.  
The impact and duration of impact of probiotic consumption on fecal microbiota diversity 
and composition were reported in July 2018 by Noh and colleagues (152). The investigators 
administered a probiotic containing Bifidobacterium, Lactobacillus, and Enterococcus for 4-
weeks. The researchers reported that microbial diversity was not statistically significantly altered 
after 4-weeks of administration, but that the relative abundances of Lactobacillus and 
Enterococcus were increased. Further, analysis of fecal microbiota 2-weeks after cessation 
revealed that the relative abundances of Lactobacillus and Enterococcus were not maintained 
and reverted to baseline abundances. The results from this study indicate that probiotics 
consumption enhance the taxa commensurate with the probiotic and that their effects are not 
maintained after cessation and suggest that maintenance may require habitual consumption of 
probiotics or dietary changes. 
 
In September 2018, a case-control study conducted by Jiang et al. compared the gut 
microbiota of individuals with generalized anxiety disorder to individuals free of any 
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psychological disorders (153). This study was among the first publications to investigate 
microbiota composition in individuals with general anxiety disorder. This study reported that 
species richness and microbial diversity were lower in subjects with generalized anxiety disorder 
compared to controls. The researchers also reported taxonomic differences between the groups. 
Four taxa were underrepresented in subjects with generalized anxiety disorders, including 
Firmicutes, Bacteroides, Ruminococcus, and Fusobacterium. In the control group, seven bacteria 
were enriched compared to the clinical group and include, Fusobacteria, Bacteroidetes, 
Faecalibacterium, Eubacterium, Sutterella, Lachnospira, and Butyricicoccus. The identification 
of differences between the two groups provides further support that the GI microbiota may play a 
role in anxiety.  
 The interrelationships among diet, GI microbiota, and mood are still not fully understood 
and additional studies are needed to establish and comprehend these complex relationships. The 
body of evidence is not sufficient to conclude that dietary enhancement, probiotics, or prebiotics 
are an efficacious or ineffective treatment for psychological disorders. Determining their efficacy 
will be partially dependent on establishing the independent effects each treatment has on 
psychological disorders, discerning microbiota differences within and between clinical 
populations, and determining how the interdependencies among diet, treatments, and the GI 
microbiota effect mood.  
The directionality and causality of the relationships among diet, GI microbiota and mood 
are still not known and this is partially due to a lack of randomized-controlled trials. Establishing 
the independent effects that diet, probiotic consumption, and prebiotic supplementation have on 
mood through randomized-controlled trials will allow for more precise treatment options and 
rule out ineffective treatments. This will require studies similar to Kazemi et al., that used 
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multiple treatments , e.g. prebiotic or probiotic consumption, to determine their effects on mood 
(150). It will also require further investigation into the effect specific bacterial strains have on 
mood disorders. The majority of the previous research used multi-strain probiotics, often with 
success. However, to use probiotics to effectively target an illness, a strain’s utility and dosage 
must first be established. Similarly, additional studies are needed to determine the effects 
prebiotics have on mood. Randomized-controlled trials are necessary to determine the effects 
that dietary enhancement, probiotic consumption, and prebiotic supplementation exert on mood. 
More specifically, dietary intervention trials with the GI microbiome as the primary outcome 
should aim to improve mood through dietary modulation of the GI microbiota. A gap in 
knowledge between GI microbiota and psychological disorders has resulted from the dearth of 
clinical trials that have included GI microbiota measures.  
Accordingly, including microbiota measures in future studies will establish the short and 
long-term effects that diet and other treatments have on the GI microbiota and mood. Bridging 
this gap in knowledge will provide insight into the roles different species have in the 
development and progression of psychological disorders by relating GI microbiota composition 
and function to mood. Further, microbiota measures will identify and characterize differences 
between clinical and non-clinical populations. Studies similar to Jiang and colleagues, that 
characterize and compare the GI microbiota of clinical populations to non-clinical populations, 
are important for identifying possible microbial signatures of disease (153). However, it is 
critical that future studies collect the participants’ dietary intake habits using dietary records or 
food frequency questionnaires. Accounting for dietary intake patterns will help reduce the 
variability in the field of microbiota-gut-brain axis research, and help increase the reproducibility 
of studies. Additionally, the use of additional “-omic” technologies will enhance the 
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identification of microbial signatures. Few studies in humans have utilized multiple -omics 
technologies and have relied mostly on microbiota compositional data via 16S sequencing. 
Compositional data allows studies to relate specific microbes to mood but does not reveal the 
functionality of the GI microbiota. Functional characteristics will provide insight into the 
contributions GI microbiota have on  mood disorders by identifying genes and metabolites 
produced by the GI microbiota.  
Determining the interdependencies among diet, GI microbiota, and mood will optimize 
the use of probiotics and prebiotics to enhance mood. The microbiota-gut-brain axis is an 
intricate bi-directional communication network that effects mood and is impacted by diet and GI 
microbiota. Thus, it is important for future studies investigating the microbiota-gut-brain axis to 
interrelate habitual diet, GI microbiota, and mood. This could be accomplished through 
adequately powered and controlled randomized-controlled trials, with a controlled-feeding and 
cross-over design. Controlled-feeding trials would control the variability in macronutrient 
composition, dietary fiber intake, and other dietary factors that may alter an indiviuals 
microbiota. The uniqueness of an individual’s microbiome may respond differently to dietary 
changes and this could be partially ameliorated with a cross-over design as each participant will 
act as their own control. A cross-over design will also provide insight into the changes that occur 
to the microbiota post-treatment and the duration of effect a treatment has on the microbiota. 
 The influence mood has on dietary choices and how this may lead to altered GI 
microbiota must also be taken into consideration. Low diet quality, increased fast-food 
consumption, and decreased fruit and vegetable consumption have been associated with mood 
disorders, and it is also likely that these factors would impact the GI microbiota. Adequately 
powered and contolled studies are needed to measure the impact mood has on dietary choices 
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and GI microbiota.These suggestions for future studies are not exhaustive, but are necessary to 
advance the current knowledge. Once future studies have established the role diet and gut 
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